Skip to Content
Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

More News and Insights

  • Contineum Therapeutics, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Contineum Therapeutics, Inc. (CTNM $3.93), a clinical-stage biotech developing small-molecule therapeutics for high-unmet-need indications in the prevalent neuroinflammation and immunology space.

    Read more
  • 365 Retail Markets Has Agreed to Acquire Cantaloupe

    William Blair acted as financial advisor to 365 Retail Markets, LLC, a portfolio company of Providence Equity Partners L.L.C., in connection with its pending acquisition of Cantaloupe, Inc. (NASDAQ: CTLP).

    Read more
  • Economics Weekly: Snapshot of a Slowing Labor Market

    In this Economics Weekly, Richard de Chazal takes a fresh look at the latest employment data.

    Read more

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures